Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
AbbVie's two newest drugs are growing so fast they've rewritten the company's entire story, and Wall Street may not have fully priced in what happens when the July 31 earnings report confirms it.
Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1 franchise.
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck (NYSE:MRK) reported that KEYTRUDA met its primary endpoint of progression free survival in the Phase 3 KEYNOTE C93 trial for advanced or recurrent endometrial cancer. The company highlighted this as the first time a PD 1 inhibitor has shown a statistically significant benefit over platinum chemotherapy in this patient population. The data are described as a high impact development for Merck's oncology portfolio, with potential implications for future regulatory filings. For investors...
In July 2026, Aurobindo Pharma announced a royalty-free, non-exclusive licensing deal with Merck to supply generic alimatravir for HIV prevention across 129 low- and middle-income countries, while Merck also secured U.S. FDA approval for LIPFENDRA, the first oral PCSK9 inhibitor for lowering LDL cholesterol. Together, these moves highlight Merck’s twin push to expand access to an investigational monthly HIV PrEP pill globally and grow its cardiovascular portfolio with a new oral...
Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe’s one-time treatments can halve the risk of heart attacks and strokes. Scribe’s therapies turn off the genetic instructions leading to high levels of damaging lipids, without having to cut a gene’s DNA strands like other one-shot genetic treatments in the clinic.
BMY heads into Q2 earnings with growth drugs driving momentum as legacy products decline, setting the stage for a closely watched earnings report.
LGND stock has risen more than 56.5% so far in 2026. Ligand doesn't make drugs; it forks over funding in exchange for Big Pharma royalties.
AstraZeneca tops Q2 earnings and revenue estimates as strong demand for oncology and rare disease drugs helps offset growing generic competition across key products.
Kimmtrak's sales growth supports IMCR, but premium valuation and reliance on one product keep investors focused on upcoming pipeline catalysts.
IMCR's Kimmtrak sales climbed 29% in 2025 on wider adoption, with pivotal 2026 trial results set to test its next expansion opportunity.
Applying the Dogs of the Dow logic across the entire S&P 500 sounds like a recipe for chasing troubled dividends, but a holding-by-holding look at SDOG reveals a more complicated picture, with two positions that deserve serious scrutiny before you commit capital.
Eli Lilly just won FDA clearance for an oral GLP-1 that targets over one billion potential patients worldwide, and the stock has barely moved. Here is whether that disconnect signals a buying opportunity or a trap.
Summit posts a wider Q2 loss with no revenues as ivonescimab advances through late-stage studies, undergoes FDA review & gains new development collaborations.
GILD's HIV franchise gains momentum with strong Biktarvy and Descovy demand, Yeztugo growth and a promising pipeline targeting long-term expansion.
Merck (MRK) is back in focus for investors after the US Food and Drug Administration approved LIPFENDRA, the first oral PCSK9 inhibitor. This adds a new cardiovascular drug to the company’s portfolio. See our latest analysis for Merck. Merck’s share price is $127.47, with a 30-day share price return of 10.38% and a year-to-date share price return of 19.75%. The 1-year total shareholder return of 56.86% reflects strong momentum alongside frequent product and trial updates. If LIPFENDRA’s...
SCHD's 100-stock structure and rock-bottom fees make it a retiree favorite, but a closer look at its top four holdings reveals one company sitting on a patent cliff that could quietly reshape its income story after 2028.
Shareholders of Organon & Co. (NYSE:OGN) approved the company’s proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting held Wednesday, according to preliminary voting results announced during the meeting. The special meeting was convened solely to cons
GSK's Specialty Medicines unit is expected to post double-digit CER growth in Q2, driven by newer HIV, RI&I and oncology drugs despite legacy pressures.
While the Dow Jones (^DJI) represents industry leaders, not every stock in the index is a safe bet. Some are facing headwinds like declining demand, rising costs, or disruptive new competitors.
Big Pharma is buying its way out of the patent cliff, while Novartis AG (NYSE:NVS) is trying to out-develop it. A Record Year for Biotech Deals The scale of that buying activity appears in this year’s deal totals. Biotech M&A has hit a record pace in 2026, with deal value reaching $216 billion so far […]
ABBV's Q2 oncology revenues may edge lower as Imbruvica weakness outweighs gains from Venclexta and newer cancer therapies.
Keytruda is expected to drive another strong quarter for MRK, with investors watching Q2 sales and management's outlook ahead of the drug's 2028 patent expiry.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
